Hobbs C J, Plymate S R, Rosen C J, Adler R A
Department of Clinical Investigation, Madigan Army Medical Center, Tacoma, Washington 98493.
J Clin Endocrinol Metab. 1993 Sep;77(3):776-9. doi: 10.1210/jcem.77.3.7690364.
Although testosterone (T) administration can increase insulin-like growth factor-I (IGF-I) when administered to hypogonadal men, no studies have examined whether this occurs in normal men. The present study was undertaken to determine if an increase in IGF-I may be part of the anabolic effect of androgens. We enrolled 11 normal men in a randomized, double-blinded cross-over study. Subjects were assigned to receive either T enanthate (TE) (300 mg im, each week) or nandrolone (ND) decanoate (300 mg im, each week) for 6 weeks. After a washout period subjects were administered the alternate treatment. Pre- and posttreatment serum was analyzed for IGF-I by RIA after acid-ethanol extraction. Results expressed as mean +/- SEM (Table 1). IGF-binding protein-3 was measured by RIA and was unchanged in the TE treatment and decreased significantly after ND treatment. Although GH levels were not significantly different after either TE or ND treatment, they tended to increase after TE treatment (1.23 +/- 0.28 ng/mL vs. 3.3 +/- 1.03 ng/mL) but remained unchanged after ND treatment (1.68 +/- 0.68 ng/mL vs. 1.89 +/- 0.64 ng/mL). Serum total T levels increased 32 +/- 0.05 nmol/L in the TE-treated men, but fell by 7 +/- 0.02 nmol/L in the ND-treated men (P < 0.0001). Serum estradiol levels rose by 193.04 +/- 19.82 pmol/L in the TE-treated men although falling by 50.65 +/- 34.50 pmol/L in the ND-treated men (P < 0.0002). These data indicate that when normal men are given TE, serum IGF-I levels increase after 6 weeks of treatment. Treatment with ND did not change serum levels of IGF-I but did decrease the level of the major serum IGF-BP and therefore the level of bioavailable IGF-I may be increased in the ND group.
虽然对性腺功能减退的男性给予睾酮（T）治疗可增加胰岛素样生长因子-I（IGF-I），但尚无研究探讨这种情况是否会发生在正常男性身上。本研究旨在确定IGF-I的增加是否可能是雄激素合成代谢作用的一部分。我们招募了11名正常男性参与一项随机、双盲交叉研究。受试者被分配接受庚酸睾酮（TE）（每周300mg，肌肉注射）或癸酸诺龙（ND）（每周300mg，肌肉注射）治疗6周。经过洗脱期后，受试者接受替代治疗。酸乙醇提取后，采用放射免疫分析法（RIA）分析治疗前后血清中的IGF-I。结果以平均值±标准误表示（表1）。采用RIA法测定IGF结合蛋白-3，在TE治疗中其水平未发生变化，而在ND治疗后显著降低。虽然TE或ND治疗后生长激素（GH）水平无显著差异，但TE治疗后GH水平有升高趋势（1.23±0.28ng/mL对3.3±1.0³ng/mL），而ND治疗后GH水平保持不变（1.68±0.68ng/mL对1.89±0.64ng/mL）。TE治疗组男性血清总T水平升高32±0.05nmol/L，而ND治疗组男性血清总T水平下降7±0.02nmol/L（P<0.0001）。TE治疗组男性血清雌二醇水平升高193.04±19.82pmol/L，而ND治疗组男性血清雌二醇水平下降50.65±34.50pmol/L（P<0.0002）。这些数据表明，正常男性接受TE治疗6周后，血清IGF-I水平会升高。ND治疗未改变血清IGF-I水平，但降低了主要血清IGF结合蛋白水平，因此ND组中生物活性IGF-I水平可能升高。
